Clinical trials: sponsored by Merck Sharp & Dohme LLC
Heart Failure
Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure
Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- TAILORD-HF (NCT06847438)
- Testing
- Optimized version of the EPIC-HF Checklist, Clinician-facing Decision Support, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 3,966 people
- Sponsor
- Emory University
Non Small Cell Lung Cancer Metastatic
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor)…
- Trial name
- KeyPemls-004 (NCT05599789)
- Testing
- Pembrolizumab in Combination with Plinabulin and Docetaxel
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking Union Medical College Hospital
Parkinson's Disease (PD), Parkinson's Disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
This clinical study is being conducted to learn more about a new imaging drug called [18F]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD).
- Conditions
- Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- Trial name
- NCT07348250
- Testing
- [18F]MK-0947
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Metastatic Triple Negative Breast Cancers
Sac-TMT for Active TNBC Brain Metastases
This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of…
- Trial name
- BERLIN (NCT07458113)
- Testing
- Sacituzumab tirumotecan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yale University
Postoperative Insomnia, Postoperative Delirium
Efficacy of Suvorexant on Post-operative Sleep Disturbance
The study is a parallel group, double blind, randomized trial. Subjects will be recruited from individuals undergoing elective surgery for orthopedic, abdominal, urologic, gynecologic or spine reasons.
- Trial name
- NCT05823844
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Columbia University
Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma
Genitourinary Tumors With Sacituzumab Tirumotecan
RINGQUEST is a Phase 2, open-label, single arm, basket, investigator-initiated clinical trial of sacituzumab tirumotecan in patients with: Cohort 1: papillary renal carcinoma (pRCC).
- Trial name
- RINGQUEST (NCT07716917)
- Testing
- Sacituzumab Tirumotecan (SKB264)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT04471974
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Rahul Aggarwal
Carcinoma, Squamous Cell Carcinoma of Head and Neck
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .
- Conditions
- Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Prostate Cancer
- Trial name
- NCT06022757
- Testing
- XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Evopoint Biosciences Inc.
Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
- Trial name
- NCT04879329
- Testing
- disitamab vedotin, pembrolizumab
- Where
- 221 sites in United States, Argentina and 10 more
- Volunteers
- 372 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Urothelial Carcinoma
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra).
- Trial name
- NCT05911295
- Testing
- disitamab vedotin, pembrolizumab, gemcitabine
- Where
- 268 sites in United States, Argentina and 22 more
- Volunteers
- 412 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Glioma
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous…
- Trial name
- NCT05188508
- Testing
- Pembrolizumab, Olaparib and Temozolomide
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hypertension, Pulmonary
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH).
- Trial name
- HARMONIZE (NCT06814145)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Belgium and 10 more
- Volunteers
- 440 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.
- Trial name
- NCT03786081
- Testing
- Tisotumab Vedotin, Bevacizumab, Pembrolizumab
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 214 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone…
- Trial name
- NCT04895358
- Testing
- pembrolizumab, paclitaxel, nab-paclitaxel
- Where
- 256 sites in United States, Argentina and 29 more
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastases
Pembrolizumab In Central Nervous System Metastases
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
- Trial name
- NCT02886585
- Testing
- Pembrolizumab, MRI, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Massachusetts General Hospital
Lung Cancer, Non-Small Cell Lung Cancer
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body.
- Trial name
- NCT06698042
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 67 sites in United States, China and 10 more
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile.
- Trial name
- NCT05467670
- Testing
- Pembrolizumab, ALX148, Doxorubicin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Alexander B Olawaiye, MD
Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases
Palbociclib and Pembrolizumab In Central Nervous System Metastases
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: Palbociclib alone (Cohort 1) The…
- Conditions
- Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
- Trial name
- NCT02896335
- Testing
- Palbociclib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Bladder Cancer
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
The purpose of this study is to find out the effectiveness of pembrolizumab in combination with BCG as a first line therapy for participants with high grade T1 bladder cancer who are at "high risk" for BCG alone to be ineffective…
- Trial name
- NCT03504163
- Testing
- Pembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG)
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center